Back to top
more

Humacyte, Inc. (HUMA)

(Delayed Data from NSDQ)

$1.46 USD

1.46
4,186,803

-0.13 (-8.18%)

Updated Nov 4, 2025 04:00 PM ET

After-Market: $1.48 +0.02 (1.37%) 5:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.63%
2Buy17.80%
3Hold9.42%
4Sell5.10%
5Strong Sell2.04%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (95 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

In the most recent trading session, Humacyte, Inc. (HUMA) closed at $1.62, indicating a -4.14% shift from the previous trading day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.71, representing a +1.18% change from its previous close.

Zacks Equity Research

Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why

by Zacks Equity Research

Humacyte, Inc. (HUMA) closed at $1.72 in the latest trading session, marking a +1.18% move from the prior day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.79, representing a +1.7% change from its previous close.

Zacks Equity Research

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors

by Zacks Equity Research

In the most recent trading session, Humacyte, Inc. (HUMA) closed at $1.65, indicating a -33.67% shift from the previous trading day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Humacyte, Inc. (HUMA) concluded the recent trading session at $1.76, signifying a +1.15% move from its prior day's close.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

Humacyte, Inc. (HUMA) concluded the recent trading session at $1.77, signifying a -4.84% move from its prior day's close.

Zacks Equity Research

Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Equity Research

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -60.00% and -73.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

Humacyte, Inc. (HUMA) concluded the recent trading session at $2.21, signifying a -4.33% move from its prior day's close.

Zacks Equity Research

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

Humacyte, Inc. (HUMA) closed at $2.4 in the latest trading session, marking a -1.23% move from the prior day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

Humacyte, Inc. (HUMA) concluded the recent trading session at $2.53, signifying a -5.24% move from its prior day's close.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

Humacyte, Inc. (HUMA) closed at $2.67 in the latest trading session, marking a -2.2% move from the prior day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

Humacyte, Inc. (HUMA) concluded the recent trading session at $2.33, signifying a -3.72% move from its prior day's close.

Zacks Equity Research

Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today

by Zacks Equity Research

Humacyte, Inc. (HUMA) closed at $2.28 in the latest trading session, marking a -7.69% move from the prior day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.54, representing a -1.17% change from its previous close.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Humacyte, Starbucks, Oracle in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.09, representing a -1.42% change from its previous close.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should Know

by Zacks Equity Research

In the latest trading session, Humacyte, Inc. (HUMA) closed at $2.19, marking a -1.79% move from the previous day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Humacyte, Inc. (HUMA) concluded the recent trading session at $2.36, signifying a +1.29% move from its prior day's close.

Zacks Equity Research

Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Humacyte, Inc. (HUMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks Equity Research

Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 47.37% and 2.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

by Zacks Equity Research

The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.45, representing a +1.4% change from its previous close.

Zacks Equity Research

All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy

by Zacks Equity Research

Humacyte, Inc. (HUMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Humacyte, Inc. (HUMA) Ascends But Remains Behind Market: Some Facts to Note

by Zacks Equity Research

Humacyte, Inc. (HUMA) reachead $1.48 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.